TQB3454 in mutant IDH1 advanced cholangiocarcinoma (CCA): Results of a phase I dose escalation and expansion study cohort

被引：1
|
作者：
Yuan, J. [1 ]
Zheng, Y. [2 ]
Xu, L. [3 ]
Xie, F. [4 ]
Gu, S. [5 ]
Li, Q. [6 ]
Zhang, J. [7 ]
Ba, Y. [8 ]
Huaxin, D. [9 ]
Yang, A. [10 ]
Li, J. [10 ]
Zhou, J. [11 ]
Shen, L. [11 ]
机构：
[1] Peking Univ, Dept Gastrointestinal Oncol, Canc Hosp Inst, Beijing, Peoples R China
[2] Zhejiang Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China
[3] Sun Yat Sen Univ, Dept Liver Surg, Canc Ctr, Guangzhou, Peoples R China
[4] Chinese PLA Naval Mil Med Univ, Dept Surg, Affiliated Hosp 3, Shanghai, Peoples R China
[5] Hunan Canc Hosp, Intervent Div, Changsha, Peoples R China
[6] SCU Sichuan Univ, Dept Oncol, Huaxi Campus, Chengdu, Peoples R China
[7] Southern Med Univ, Dept Oncol, ZhuJiang Hosp, Zhujiang, Peoples R China
[8] Tianjin Med Univ, Dept Gastroenterol, Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hunan Prov Peoples Hosp, Dept Oncol, Changsha, Peoples R China
[10] CTTQ Chia Tai Tianqing Pharmaceut Grp Co Ltd, Clin Med, Lianyungang, Peoples R China
[11] Peking Univ Canc Hosp & Inst, GI Oncol Dept, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.292
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286P
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [1] Ivosidenib in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 17 - 20
  • [2] Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.
    Lowery, Maeve Aine
    Abou-Alfa, Ghassan K.
    Burris, Howard A.
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer Saba
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Ishii, Yuko
    Auer, Julia
    Gliser, Camelia
    Agresta, Samuel V.
    Pandya, Shuchi Sumant
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
    DiNardo, Courtney D.
    De Botton, Stephane
    Stein, Eytan M.
    Roboz, Gail J.
    Mims, Alice S.
    Pollyea, Daniel A.
    Swords, Ronan T.
    Altman, Jessica K.
    Collins, Robert H.
    Mannis, Gabriel N.
    Uy, Geoffrey L.
    Donnellan, Will
    Pigneux, Arnaud
    Fathi, Amir T.
    Stein, Anthony S.
    Erba, Harry P.
    Prince, Gabrielle T.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Yen, Katharine
    Kapsalis, Stephanie M.
    Liu, Hua
    Goldwasser, Meredith
    Agresta, Sam
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    BLOOD, 2017, 130
  • [4] TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study
    Xue, Junli
    Xue, Liqiong
    Tang, Wenbo
    Ge, Xiaoxiao
    Zhao, Wei
    Li, Qun
    Peng, Wei
    Dai, Congqi
    Guo, Ye
    Li, Jin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [5] Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study
    Fan, Bin
    Abou-Alfa, Ghassan K.
    Zhu, Andrew X.
    Pandya, Shuchi Sumant
    Jia, Hongxia
    Yin, Feng
    Jiang, Liewen
    Gliser, Camelia
    Yang, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
    Tap, William D.
    Villalobos, Victor M.
    Cote, Gregory M.
    Burris, Howard
    Janku, Filip
    Mir, Olivier
    Beeram, Murali
    Wagner, Andrew J.
    Jiang, Liewen
    Wu, Bin
    Choe, Sung
    Yen, Katharine
    Gliser, Camelia
    Fan, Bin
    Agresta, Sam
    Pandya, Shuchi S.
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1693 - +
  • [7] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Harding, J.
    Ikeda, M.
    Goyal, L.
    Rodon, J.
    Bai, L.
    Oh, D.
    Park, J.
    Chen, L.
    Ueno, M.
    Liao, C.
    Kondo, S.
    Cosman, R.
    Yokota, T.
    Shroff, R.
    Satoh, T.
    Palmieri, L.
    Hollebecque, A.
    Adeva, J.
    Bender, M.
    Liu, H.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S161 - S161
  • [8] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
    Pauff, James Michael
    Papadopoulos, Kyriakos P.
    Janku, Filip
    Turk, Anita Ahmed
    Goyal, Lipika
    Shroff, Rachna T.
    Shimizu, Toshio
    Ikeda, Masafumi
    Azad, Nilofer Saba
    Cleary, James M.
    Peters, Mary Linton Bounetheau
    Borad, Mitesh J.
    Jaeckle, Kurt A.
    Kizilbash, Sani Haider
    Tupper, Rebecca
    Furin, Carrie E.
    Hanley, Matthew P.
    Hill, Elizabeth Goodwin
    Xu Xiaojian
    Harding, James J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [9] AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
    Mellinghoff, Ingo K.
    Touat, Mehdi
    Maher, Elizabeth
    DeLaFuente, Macarena
    Cloughesy, Timothy F.
    Holdhoff, Matthias
    Cote, Gregory
    Burris, Howard
    Janku, Filip
    Huang, Raymond
    Young, Robert
    Ellingson, Benjamin
    Auer, Julia
    Liu, Hua
    Hurov, Jonathan
    Yen, Katherine
    Agresta, Sam
    Attar, Eyal
    Pandya, Susan
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2016, 18 : 12 - 12
  • [10] Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
    Natsume, Atsushi
    Wakabayashi, Toshihiko
    Miyakita, Yasuji
    Narita, Yoshitaka
    Mineharu, Yohei
    Arakawa, Yoshiki
    Yamasaki, Fumiyuki
    Sugiyama, Kazuhiko
    Hata, Nobuhiro
    Muragaki, Yoshihiro
    Nishikawa, Ryo
    Shinojima, Naoki
    Kumabe, Toshihiro
    Saito, Ryuta
    Ito, Kazumi
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Nishijima, Soichiro
    Tsubouchi, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345